On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
REGULATORY
MHLW to Run Fresh Survey on Drug Makers’ Responses to Promotion Guidelines
The Ministry of Health, Labor and Welfare (MHLW) plans to launch a new survey as early as this month to follow up on how pharmaceutical makers are faring in responding to its ethical drug promotion guidelines enforced in 2019, people…
To read the full story
Related Article
- Companies Should Reward Consistent Compliance with Detailing Guidelines in Performance Evaluations: MHLW Study
April 6, 2020
- MHLW to Set Up New Study Group on Detailing Activities Report System for All Medical Institutions
January 6, 2020
- Promotion Guidelines Now in Full Effect, MHLW Starts Survey to Capture Leading Examples of Company Set-Ups
December 17, 2019
- Wholesalers Working Out Systems to Comply with Promotion Guidelines, Show Mixed Approaches to External Oversight
October 8, 2019
- New Detailing Guidelines Go into Full Effect on October 1, Making Supervisory Systems Mandatory
October 1, 2019
- Drug Makers Scratching Heads to Meet Daily Rep Report Requirements for New Detailing Guidelines
April 10, 2019
- New Detailing Guidelines Take Effect on April 1; Q&A on Information Supply on Unapproved Drugs/Indications Issued
April 2, 2019
- Drug Makers, Wholesalers Establishing Supervisory Divisions as Detailing Guidelines Rollout Nears
March 15, 2019
- MHLW Issues Guidelines on Detailing Activities by Sales Reps; to Take Effect Next April
September 27, 2018
- MHLW to Introduce Guidelines for Sales Reps’ Activities, Calling for the Creation of Supervising Offices
July 17, 2018
REGULATORY
- Administrative Penalty on Nichi-Iko Possible by March-End over Recalls
January 15, 2021
- Special Mitigation Margin for COVID-19 Up for Debate towards FY2022 Drug Price Revision: MHLW Bureau Chief
January 15, 2021
- MHLW Initiates Discussions on Amendment of Clinical Research Law
January 15, 2021
- Thaled Up for PAFSC Review for POEMS Syndrome on Jan. 27
January 15, 2021
- Chuikyo to Discuss Health Coverage for Fertility Treatments from This Summer
January 14, 2021
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…